• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Shalash, M., Kandil, N., Fathalla, R., Alsaadany, O., Radwan, A. (2024). ADIPOCYTES FATTY ACID BINDING PROTEIN AND ITS RELATION TO SUBCLNICAL ATHEROSCLEROSIS IN SUBJECTS WITH TYPE 2 DIABETES. ALEXMED ePosters, 6(1), 25-26. doi: 10.21608/alexpo.2024.268502.1782
Magui Abd Elmonem Shalash; Noha Said Kandil; Reem Fathalla; Omnia Ezz Eldin Fathy Alsaadany; Aya Fathy Radwan. "ADIPOCYTES FATTY ACID BINDING PROTEIN AND ITS RELATION TO SUBCLNICAL ATHEROSCLEROSIS IN SUBJECTS WITH TYPE 2 DIABETES". ALEXMED ePosters, 6, 1, 2024, 25-26. doi: 10.21608/alexpo.2024.268502.1782
Shalash, M., Kandil, N., Fathalla, R., Alsaadany, O., Radwan, A. (2024). 'ADIPOCYTES FATTY ACID BINDING PROTEIN AND ITS RELATION TO SUBCLNICAL ATHEROSCLEROSIS IN SUBJECTS WITH TYPE 2 DIABETES', ALEXMED ePosters, 6(1), pp. 25-26. doi: 10.21608/alexpo.2024.268502.1782
Shalash, M., Kandil, N., Fathalla, R., Alsaadany, O., Radwan, A. ADIPOCYTES FATTY ACID BINDING PROTEIN AND ITS RELATION TO SUBCLNICAL ATHEROSCLEROSIS IN SUBJECTS WITH TYPE 2 DIABETES. ALEXMED ePosters, 2024; 6(1): 25-26. doi: 10.21608/alexpo.2024.268502.1782

ADIPOCYTES FATTY ACID BINDING PROTEIN AND ITS RELATION TO SUBCLNICAL ATHEROSCLEROSIS IN SUBJECTS WITH TYPE 2 DIABETES

Article 1, Volume 6, Issue 1, January 2024, Page 25-26  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.268502.1782
View on SCiNiTO View on SCiNiTO
Authors
Magui Abd Elmonem Shalash1; Noha Said Kandil2; Reem Fathalla3; Omnia Ezz Eldin Fathy Alsaadany4; Aya Fathy Radwan email 1
1Department of Internal Medicine, Faculty of Medicine, University of Alexandria
2Department of Hematology, Medical Research Institute, Alexandria University
3Department of Internal Medicine, Faculty of Medicine, Alexandria University
4Department of Radiodiagnosi, Faculty of Medicine, University of Alexandria
Abstract
Diabetes mellitus (DM) is the most common endocrine disorderwhichcharacterized by high blood sugar levels over prolonged periods.
Although the precise mechanisms through which diabetes increases the likelihood of atherosclerotic plaque formation are not completely defined, the association between the two is profound.
Atherosclerotic cardiovascular disease (ASCVD) remains the principal cause of death and disability among patients with diabetes mellitus, especially in those with type 2 diabetes mellitus in whom it typically occurs 14.6 years earlier, with greater severity, and with more diffuse distribution than in individuals without diabetes mellitus.
Furthermore, about two-thirds of deaths in people with diabetes mellitus are attributable to cardiovascular disease: of these, ≈40% are from ischemic heart disease, 15% from other forms of heart disease, principally congestive heart failure, and ≈10% from stroke.
Intensive treatment of multiple cardiovascular risk factors can have a major impact among patients with diabetes. Reduction in glycosylated hemoglobin values, systolic and diastolic blood pressure, fasting serum cholesterol and triglyceride levels, and urinary albumin excretion rate all have their value in reducing cardiovascular morbidity and mortality.
Adipocytes produce and secrete a variety of bioactive peptides, termed adipokines, which influence body weight, insulin sensitivity, lipid metabolism and vascular function. Adipocyte fatty acid binding protein (AFABP), also known as fatty acid binding protein-4 and aP2, has recently been suggested as a third adipokine, in addition to leptin and adiponectin, that is preferentially produced in and released from adipocytes.
Keywords
Diabetes mellitus (DM); SUBCLNICAL ATHEROSCLEROSIS; ADIPOCYTES FATTY ACID BINDING PROTEIN
Supplementary Files
download 1782 22 (22).pdf
Statistics
Article View: 75
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.